Semaglutide, Tirzepatide, and Retatrutide are three of the most discussed compounds in GLP-1 and metabolic research.
They are often compared because they sit in the same broad research category but have different receptor profiles.
Semaglutide is commonly discussed as a GLP-1 receptor agonist. Tirzepatide is commonly discussed as a dual GIP and GLP-1 receptor agonist. Retatrutide is commonly discussed as a triple GIP, GLP-1, and glucagon receptor agonist.
That receptor difference is why buyers, researchers, and peptide shoppers compare them so often.
The interest is real.
These compounds are discussed in appetite, satiety, glucose regulation, incretin signaling, body-weight research, fat-loss research, obesity research, and broader metabolic studies. Clinical research involving regulated drug products and investigational compounds has reported major body-weight findings for Semaglutide, Tirzepatide, and Retatrutide. But that research does not make research-use vials sold online approved for human consumption, equivalent to prescription products, or appropriate for personal use.
This guide compares Semaglutide vs Tirzepatide vs Retatrutide from a research-use buyer perspective. It explains receptor activity, research context, COA review, purity claims, vial sizes, storage, and supplier transparency.
Axis Regeneration products are sold for laboratory and research use only. They are not approved for human consumption, medical use, diagnosis, treatment, cure, or prevention of disease.
The simplest difference is receptor activity.
Semaglutide is commonly discussed as a GLP-1 receptor agonist. Tirzepatide is commonly discussed as a dual GIP and GLP-1 receptor agonist. Retatrutide is commonly discussed as a triple GIP, GLP-1, and glucagon receptor agonist.
That means:
These receptor profiles explain why all three are discussed in body-weight and metabolic research. They do not mean research-use products sold online are approved for human consumption or personal use.
You can review the current Semaglutide 15mg vial, Tirzepatide 15mg vial, and Retatrutide 40mg vial in the Axis Regeneration shop.
| Category | Semaglutide | Tirzepatide | Retatrutide |
|---|---|---|---|
| Common research category | GLP-1 receptor agonist | Dual GIP/GLP-1 receptor agonist | Triple GIP/GLP-1/glucagon receptor agonist |
| Main receptor profile | GLP-1 | GIP + GLP-1 | GIP + GLP-1 + glucagon |
| Main research interest | Appetite, satiety, glucose regulation, body-weight research | Dual incretin signaling, glucose regulation, body-weight research | Triple agonist research, energy expenditure, body-weight research |
| Why buyers compare it | GLP-1 benchmark compound | Dual receptor comparison | Next-generation triple receptor comparison |
| Axis product | Semaglutide 15mg vial | Tirzepatide 15mg vial | Retatrutide 40mg vial |
| Research-use only? | Yes | Yes | Yes |
| Human-use claims allowed? | No | No | No |
Buyers compare Semaglutide, Tirzepatide, and Retatrutide because all three appear in the GLP-1 and incretin research conversation.
They want to understand:
Those are reasonable research and buyer-review questions.
They can be answered without giving human-use guidance.
A careful comparison explains receptor profiles, research categories, documentation, and product transparency. It does not tell buyers how to use the compounds.
GLP-1 stands for glucagon-like peptide-1.
GLP-1 is an incretin hormone involved in metabolic signaling. GLP-1 receptor activity is commonly discussed in relation to appetite signaling, satiety, gastric emptying, insulin secretion, glucagon suppression, glucose regulation, energy intake, and body-weight research.
Semaglutide, Tirzepatide, and Retatrutide all appear in the broader GLP-1 research conversation.
The difference is that Semaglutide is commonly discussed as GLP-1-focused, Tirzepatide adds GIP receptor activity, and Retatrutide adds both GIP and glucagon receptor activity.
For more detail, read GLP-1 Research Compounds Explained.
GIP stands for glucose-dependent insulinotropic polypeptide.
GIP is another incretin hormone. It is discussed in relation to insulin response, glucose regulation, lipid metabolism, and broader metabolic signaling.
GIP matters in this comparison because Tirzepatide and Retatrutide both include GIP receptor activity in common research descriptions.
That means:
This is one of the main reasons Tirzepatide and Retatrutide are often described as next-generation incretin research compounds.
Glucagon is a hormone involved in glucose and energy regulation.
In Retatrutide research, glucagon receptor activity receives attention because of its possible relationship to energy expenditure, hepatic metabolism, fat metabolism research, and broader metabolic signaling.
This is the key feature that separates Retatrutide from Tirzepatide.
Tirzepatide is commonly discussed as dual GIP/GLP-1.
Retatrutide is commonly discussed as triple GIP/GLP-1/glucagon.
The added glucagon receptor activity is why Retatrutide receives strong attention in next-generation obesity and metabolic research.
Semaglutide is commonly discussed as a GLP-1 receptor agonist.
That means its research category is focused on GLP-1 receptor activity.
GLP-1 receptor activity is commonly associated with:
Semaglutide became one of the best-known compounds in the broader GLP-1 category because of its role in diabetes, obesity, body-weight, and metabolic research.
For research-use buyers, the key review points are:
Axis currently lists the Semaglutide 15mg vial.
For more detail, read What Is Semaglutide?.
Tirzepatide is commonly discussed as a dual GIP and GLP-1 receptor agonist.
That makes it different from Semaglutide.
Semaglutide is commonly discussed as GLP-1-focused. Tirzepatide is discussed as involving both GIP and GLP-1 receptor pathways.
This dual incretin model is one reason Tirzepatide became one of the most compared compounds in the metabolic research category. FDA labeling for Zepbound describes tirzepatide as a GIP receptor and GLP-1 receptor agonist.
Research discussions around Tirzepatide often focus on:
Axis currently lists the Tirzepatide 15mg vial.
For more detail, read What Is Tirzepatide?.
Retatrutide is commonly discussed as a triple agonist involving GIP, GLP-1, and glucagon receptor activity.
That triple receptor profile is the main reason Retatrutide receives so much attention.
It is often compared with Semaglutide and Tirzepatide because it appears to represent another step in incretin-based metabolic research:
A Phase 2 obesity trial published in The New England Journal of Medicine described Retatrutide as an agonist of GIP, GLP-1, and glucagon receptors and reported substantial body-weight reductions over 48 weeks in adults with obesity.
Those findings explain why Retatrutide attracts strong search interest.
They do not mean research-use Retatrutide products sold online are approved, equivalent to investigational clinical-trial products, or appropriate for human use.
Axis currently lists the Retatrutide 40mg vial.
For more detail, read What Is Retatrutide?.
All three compounds are discussed in body-weight research.
That is one of the main reasons people search them.
Semaglutide is widely discussed because GLP-1 receptor activity is connected to appetite, satiety, glucose regulation, and body-weight research.
Tirzepatide is discussed because dual GIP/GLP-1 receptor activity is connected to incretin signaling, metabolic research, and body-weight studies.
Retatrutide is discussed because triple GIP/GLP-1/glucagon receptor activity adds another receptor pathway to the metabolic research conversation.
Clinical studies involving regulated or investigational products help explain the attention around these compounds. But research findings do not make research-use vials sold online approved for human consumption, prescription-equivalent, or suitable for personal use. FDA has warned about unapproved GLP-1 products sold online, including products containing Semaglutide, Tirzepatide, or Retatrutide that are falsely labeled “for research purposes” or “not for human consumption” while being sold for human use.
People often compare Semaglutide, Tirzepatide, and Retatrutide because they are interested in weight loss and fat loss.
That search intent is real.
But wording matters.
Clinical studies often report body-weight reduction. Body weight may include fat mass, lean mass, water, glycogen, and other components. Fat loss specifically refers to fat-mass reduction.
Careful research terms include:
Riskier product terms include:
Research-use content can mention body-weight and fat-mass research where appropriate.
It should not present products as fat-loss tools.
There is no universal “best” research compound.
Semaglutide, Tirzepatide, and Retatrutide differ by receptor profile, research context, documentation, vial size, and product availability.
From a buyer-review perspective, the better question is not:
“Which one is best?”
The better question is:
“Which product listing is clearest, best documented, and most transparent?”
Buyers should review:
A well-documented product page is more useful than a vague page with hype.
Receptor profile gets most of the attention.
But buyers should not compare these compounds only by receptor activity.
They should also compare product transparency.
A product listing should answer:
A strong product page makes these answers easy to find.
COA review matters for Semaglutide, Tirzepatide, and Retatrutide.
A useful COA may include:
A COA should match the product being sold.
A Semaglutide COA should not support Tirzepatide.
A Tirzepatide COA should not support Retatrutide.
A Retatrutide COA should not support Semaglutide.
A COA from one batch should not be used to imply another batch was tested unless the supplier clearly explains the relationship.
For a full review process, read How to Read a Peptide COA Before Buying.
GLP-1 research product pages may advertise high purity.
A product may say:
Those numbers can be useful when they are supported by documentation.
A strong purity claim should connect to:
Purity does not prove:
For more detail, read What Does Peptide Purity Mean?.
Third-party testing is especially important for high-demand compounds because high demand attracts weak sellers.
A third-party COA can help support:
But third-party testing still has limits.
It does not automatically prove human safety, approval, sterility, endotoxin status, exact vial fill, equivalence to prescription products, or clinical effectiveness.
For more detail, read Why Third-Party Testing Matters for Peptides.
Axis currently lists:
Vial size is product identification information.
It is not dosing guidance.
A larger vial is not automatically better. A lower price per milligram is not automatically better. A high purity number does not automatically prove fill amount.
Buyers should review vial size together with COA status, batch information, purity support, storage guidance, and supplier policies.
For more detail, read Peptide Vial Sizes Explained.
Semaglutide, Tirzepatide, and Retatrutide should not be evaluated only by price, receptor profile, or purity.
Storage and shipping matter too.
Peptides may be sensitive to:
Buyers should review:
For more detail, read How to Store Research Peptides Safely.
Research-use language is not a footer decoration.
It should shape the entire product page.
A research-use GLP-1 product page should focus on:
It should avoid:
This matters because GLP-1 products are strongly associated with human prescription drug markets.
A clear research-use page protects buyers and builds trust.
Watch for these red flags when reviewing Semaglutide, Tirzepatide, or Retatrutide products online:
For more warning signs, read Red Flags When Buying Peptides Online.
Before ordering GLP-1-category research products online, buyers should ask:
If several answers are unclear, slow down before ordering.
Axis Regeneration is building around product clarity, privacy, and research-use transparency.
For Semaglutide, Tirzepatide, and Retatrutide, buyers should be able to review:
You can browse current products in the research peptide catalog and review available COA documentation.
Review these Axis pages before ordering:
Continue with these Axis Regeneration guides:
Semaglutide is commonly discussed as a GLP-1 receptor agonist. Tirzepatide is commonly discussed as a dual GIP and GLP-1 receptor agonist. Retatrutide is commonly discussed as a triple GIP, GLP-1, and glucagon receptor agonist.
Semaglutide is commonly discussed as GLP-1-focused.
Tirzepatide is commonly discussed as targeting both GIP and GLP-1 receptor pathways.
Retatrutide is commonly discussed as targeting GIP, GLP-1, and glucagon receptor pathways.
They are discussed in body-weight research because GLP-1, GIP, and glucagon-related pathways are connected to appetite, satiety, glucose regulation, energy intake, and metabolic signaling.
No. Axis Regeneration products are sold for laboratory and research use only. They are not intended for human consumption, medical use, diagnosis, treatment, cure, or prevention of disease.
No. Research-use product pages should not provide dosing instructions, injection instructions, reconstitution guidance for self-use, or personal-use protocols.
No. A COA should match the specific compound and batch being sold. Semaglutide, Tirzepatide, and Retatrutide should not be supported by the same unrelated COA.
Buyers should review product identity, vial size, COA status, batch number, test date, purity claim, testing method, storage guidance, supplier policies, and research-use disclaimers.
You can review the Semaglutide 15mg vial, Tirzepatide 15mg vial, and Retatrutide 40mg vial in the Axis Regeneration shop.
Semaglutide, Tirzepatide, and Retatrutide are compared because they sit in the same broad GLP-1 and metabolic research category but differ by receptor profile.
Semaglutide is commonly discussed as GLP-1-focused. Tirzepatide is commonly discussed as dual GIP and GLP-1. Retatrutide is commonly discussed as triple GIP, GLP-1, and glucagon.
That difference matters for research context.
It does not turn research-use products into human-use products.
Before ordering any GLP-1-category research product online, buyers should review product identity, vial size, COA documentation, batch number, purity claim, testing method, storage guidance, shipping policy, privacy policy, and research-use language.
Axis Regeneration is building around privacy, product clarity, and research-use transparency. Review the Semaglutide 15mg vial, Tirzepatide 15mg vial, Retatrutide 40mg vial, or browse the full research peptide catalog before ordering.
Research-use disclaimer: Axis Regeneration products are sold for laboratory and research use only. They are not intended for human consumption, medical use, diagnosis, treatment, cure, or prevention of disease.